Lipoprotein removal by soluble enzymes
CA 2049119 C · Owner: Lees, Robert S. · Inventors: Mullon, Claudy J. P.; Langer, Robert S. Jr.; Lees, Robert S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A therapeutically effective amount of soluble phospholipase A2 is administered into a subject for lowering the low density lipoproteins ("LDL") in the blood. Phospholipase A2 modifies the plasma LDL by hydrolyzing the phospholipids present in LDL. As a result the modified LDL is, rapidly removed from the bloodstream by the catabolic processes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 13, 1991 and granted August 5, 1997. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 13, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 13, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.